قالب وردپرس درنا توس
Home / Health / Prostate cancer survivors more susceptible to chronic diseases

Prostate cancer survivors more susceptible to chronic diseases



  Survivors of Prostate Cancer Prone to Chronic Diseases
Credit: University of South Australia

Prostate cancer survivors taking androgen deprivation therapy (ADT), a treatment commonly used to block the release of male hormones, are at greater risk of developing chronic diseases, according to a new study published this week has been.

In a study that analyzed the pharmaceutical records of approximately 3,700 prostate cancer survivors from 2003 to 201

4, researchers from the University of South Australia (UniSA) investigated the evolution of chronic diseases over time

Data show that survivors Treated by Prostate Cancer ADTs developed more commonly cardiovascular disease, depression, diabetes, gastric acid disorders, hyperlipidemia (high cholesterol), osteoporosis, and inflammatory / painful conditions.

UniSA Ph.D. Candidate Huah Shin Ng, who conducted the study, says earlier studies have shown long-term adverse effects of ADT, but this is the first study to investigate the development of multiple chronic diseases in the Australian environment.

The results indicate a need for a better coordinated care of cancer survivors. Agnes Vitry, who oversaw the study.

"These data will help us to develop a needs-based approach to ensure optimal use of healthcare services. Multiple chronic diseases for the increasing number of cancer survivors in Australia" Dr. Vitry says.

Prostate cancer is the most common cancer in Australian men. In 2017, more than 200,000 men with prostate cancer lived in Australia. Of these, 80 percent are long-term survivors, but many will die of causes other than prostate cancer, mainly of chronic diseases, which contributes to a spiral of health legislation.

There are no hard numbers for Australia, but a report released in the UK showed that hospital costs for prostate cancer survivors with comorbidities amounted to £ 12,000 compared to £ 2,800 for survivors without chronic health conditions

The publication "Development of Comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study "published in Prostate Cancer and Prostatic Diseases .


Further information:
PSA level three months after the irradiation tx can predict the outcome

Further information:
Huah Shin Nget al. Development of Comorbidities in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: An Australian Population-Based Cohort Study, Prostate Cancer and Prostate Diseases (2018). DOI: 10.1038 / s41391-018-0036-y

Provided by:
University of South Australia


Source link